共 50 条
- [41] EORTC-1416-LCG/ETOP 8-15-PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)O'Brien, Mary E. R.Paz-Ares, LuisJha, NitishDafni, UraniaOselin, KerstiHavel, LiborEsteban, EmilioIsla, DoloresMartinez-Marti, AlexFaehling, MartinTsuboi, MasahiroLee, Jong-SeokNakagawa, KazuhikoYang, JingKeller, Steven M.Mauer, MurielleMarreaud, SandrineStahel, Rolf A.Besse, BenjaminPeters, Solange
- [42] ARC-10: A phase 3 study to evaluate zimberelimab plus domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non-small-cell lung cancer.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Chouaid, ChristosHo, Gwo FuangRunglodvatana, YotsawajHe, XianAhlers, Christoph MatthiasPomponio, DebbieTodd, TreverDang, ThaoNaidoo, Jarushka
- [43] A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapyLUNG CANCER, 2016, 99 : 186 - 193Yoh, KiyotakaHosomi, YukioKasahara, KazuoYamada, KazuhikoTakahashi, ToshiakiYamamoto, NobuyukiNishio, MakotoOhe, YuichiroKoue, ToshikoNakamura, TakashiEnatsu, SotaroLee, PabloFerry, DavidTamura, TomohideNakagawa, Kazuhiko
- [44] VANDETANIB PLUS CHEMOTHERAPY FOR INDUCTION THERAPY FOLLOWED BY VANDETANIB OR PLACEBO AS MAINTENANCE FOR ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): EFFICACY AND TOXICITIES UPDATE. A PHASE II PRECOG, LLC STUDY (PRE0501)JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1258 - S1258Aisner, JosephManola, JudithDakhil, ShakerStella, Phillip J.Schiller, Joan
- [45] Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialLANCET ONCOLOGY, 2020, 21 (03): : 387 - 397Garassino, Marina C.Gadgeel, ShirishEsteban, EmilioFelip, EnriquetaSperanza, GiovannaDomine, ManuelHochmair, MaximilianPowell, SteveCheng, Susanna Yee-ShanBischoff, Helge G.Peled, NirReck, MartinHui, RinaGaron, Edward B.Boyer, MichaelWei, ZiwenBurke, ThomasPietanza, M. CatherineRodriguez-Abreu, Delvys
- [46] ORION: A Phase 2, randomized, multicenter, doubleblind study to assess efficacy and safety of durvalumab plus olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Ahn, Myung-JuLiu, YufanImprota, TeresaMarcovitz, MichelleDiPiazza, KateLanasa, Mark C.
- [47] Exploratory analysis of efficacy by histology and frontline therapies in a nonsquamous non-small cell lung cancer (NSCLC) subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC plus placebo (PBO) for second-line treatment of stage IV NSCLCONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 90 - 90Schuette, W.Reck, M.Kimmich, M.Schumann, C.Paz-Ares, L.Garon, E.Perol, M.Zimmermann, A.Lee, P.
- [48] A phase III randomized study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in early-stage non-small cell lung cancer (NSCLC): Follow-up data of Ch.ESJOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)Scagliotti, G. V.Pastorino, U.Vansteenkiste, J. F.Spaggiari, L.Facciolo, F.Orlowski, T.Maiorino, A.Hetzel, M.Visseren-Grul, C.Torri, V.
- [49] Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Paz-Ares, LuisPerol, MauriceCiuleanu, Tudor-EliadeKowalyszyn, Ruben DarioReck, MartinLewanski, Conrad R.Syrigos, Konstantinos N.Arrieta, OscarPrabhash, KumarPark, KeunchilPikiel, JoannaGoeksel, TuncayLee, Pablo SangZimmerman, AnnamariaTreat, JosephFerry, DavidMelemed, Allen S.Carter, Gebra CuyunAlexandris, EkaterineGaron, Edward B.
- [50] Exploratory analysis of efficacy by histology and frontline therapies in a nonsquamous (NSQ) non-small cell lung cancer (NSCLC) subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC plus placebo (PL) for second-line treatment of stage IV NSCLCONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 166 - 166Reck, M.Kimmich, M.Schuette, W.Schumann, C.Paz-Ares, L.Garon, E.Perol, M.Zimmermann, A.Lee, P.